Neovacs S.A. (ALNEV) - Total Assets
Based on the latest financial reports, Neovacs S.A. (ALNEV) holds total assets worth €22.14 Million EUR (≈ $25.88 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ALNEV cash flow conversion for how efficiently the company converts equity into cash flow.
Neovacs S.A. - Total Assets Trend (2007–2025)
This chart illustrates how Neovacs S.A.'s total assets have evolved over time, based on quarterly financial data. See ALNEV share price today for real-time trading data and today's change.
Neovacs S.A. - Asset Composition Analysis
Current Asset Composition (December 2025)
Neovacs S.A.'s total assets of €22.14 Million consist of 11.9% current assets and 88.1% non-current assets. Explore ALNEV working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 2.6% |
| Accounts Receivable | €1.95 Million | 8.8% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €6.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how Neovacs S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Neovacs S.A.'s current assets represent 11.9% of total assets in 2025, a decrease from 90.9% in 2007.
- Cash Position: Cash and equivalents constituted 2.6% of total assets in 2025, down from 55.1% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 21.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 8.8% of total assets.
Neovacs S.A. Competitors by Total Assets
Key competitors of Neovacs S.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
ABCELLERA BIOLOGICS
F:8QQ
|
Germany | €1.31 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥7.07 Billion |
Neovacs S.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.84 | 0.65 | 5.41 |
| Quick Ratio | 0.84 | 0.65 | 5.41 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-512.68K | €-1.34 Million | €10.68 Million |
Neovacs S.A. - Advanced Valuation Insights
This section examines the relationship between Neovacs S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 0.3% |
| Total Assets | €22.14 Million |
| Market Capitalization | $10.44 USD |
Valuation Analysis
Below Book Valuation: The market values Neovacs S.A.'s assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Neovacs S.A.'s assets grew by 0.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Neovacs S.A. (2007–2025)
The table below shows the annual total assets of Neovacs S.A. from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €22.14 Million ≈ $25.88 Million |
+0.30% |
| 2024-12-31 | €22.07 Million ≈ $25.80 Million |
-53.57% |
| 2023-12-31 | €47.53 Million ≈ $55.57 Million |
-3.55% |
| 2022-12-31 | €49.28 Million ≈ $57.62 Million |
+1.51% |
| 2021-12-31 | €48.55 Million ≈ $56.76 Million |
+260.03% |
| 2020-12-31 | €13.49 Million ≈ $15.77 Million |
+78.92% |
| 2019-12-31 | €7.54 Million ≈ $8.81 Million |
+4.12% |
| 2018-12-31 | €7.24 Million ≈ $8.46 Million |
-37.97% |
| 2017-12-31 | €11.67 Million ≈ $13.64 Million |
+25.02% |
| 2016-12-31 | €9.33 Million ≈ $10.91 Million |
-17.05% |
| 2015-12-31 | €11.25 Million ≈ $13.15 Million |
+24.27% |
| 2014-12-31 | €9.05 Million ≈ $10.59 Million |
+18.07% |
| 2013-12-31 | €7.67 Million ≈ $8.97 Million |
+23.45% |
| 2012-12-31 | €6.21 Million ≈ $7.26 Million |
-52.15% |
| 2011-12-31 | €12.98 Million ≈ $15.18 Million |
+21.57% |
| 2010-12-31 | €10.68 Million ≈ $12.48 Million |
+136.05% |
| 2009-12-31 | €4.52 Million ≈ $5.29 Million |
-48.02% |
| 2008-12-31 | €8.70 Million ≈ $10.17 Million |
+117.28% |
| 2007-12-31 | €4.01 Million ≈ $4.68 Million |
-- |
About Neovacs S.A.
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company's product pipeline includes Kinoid, a therapeutic vaccine which allows the immune system to generate natural polyclonal antibodies. IF… Read more